1 |
Mohamed SF, Mohamed HAD (2012). The expression of cyclooxygenase-2 and survivin in urinary bladder transitional cell carcinoma. Egyp J Pathol, 32, 150-4
DOI
|
2 |
Naruse K, Yamada Y, Nakamura K, et al (2010). Potential of molecular targeted therapy of HER-2 and COX-2 for invasive transitional cell carcinoma of the urinary bladder. Oncol Rep, 23, 1577-83.
|
3 |
Okamoto A, Shirakawa T, Bito T, et al (2008). Etodolac ,a selective cyclooxygenase-2 inhibitor , induces upregulation of E-Cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology, 71, 156-60.
DOI
ScienceOn
|
4 |
Parkin DM (2008). The global burden of urinary bladder cancer. Scand J Urol Nephrol Suppl, 218, 12-20.
|
5 |
Pruthi RS, Derksen E, Gaston K, Wallen EM (2004). Rationale for use of cyclooxygenase-2 inhibitors in prevention and treatment of bladder cancer. Urology, 64, 637-42.
DOI
ScienceOn
|
6 |
Raspollini MR, Taddei GL (2007). Cyclooxygenase -2: a novel target in human solid tumors. Curr Oncol Rep, 9, 96-101.
DOI
ScienceOn
|
7 |
Ristimaki A, Nieminen O, Saukkonen K, et al (2001). Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol, 158, 849-53.
DOI
ScienceOn
|
8 |
Sadjadi A, Nouraie M, Mohagheghi M, et al (2005). Cancer Occurrence in Iran in 2002, an International Perspective. Asian Pac J Cancer Prev, 6, 359-63.
|
9 |
Shariat SF, Kim JH, Ayala GE, et al (2003a). Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol, 169, 938-42.
DOI
ScienceOn
|
10 |
Shariat SF, Matsumoto K, Kim J, et al (2003b).Correlation of cyclooxygenase-2 expression with molecular markers, pathological features and clinical outcome of transitional cell carcinoma of the bladder. J Urol, 170, 985-9.
DOI
ScienceOn
|
11 |
Shirahama T (2000). Cyclooxygenase-2 expression is up-regulated in transitional cell carcinoma and its preneoplastic lesions in the human urinary bladder. Clin Cancer Res, 6, 2424-30.
|
12 |
Shirahama T, Arima J, Akiba S, Sakakura C (2001). Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder. Cancer, 92, 188-93.
DOI
ScienceOn
|
13 |
Song T, Zhang X, Wang C, et al (2011). Expression of miR-143 reduces growth and migration of human bladder carcinoma cells by targeting cyclooxygenase-2. Asian Pac J Cancer Prev, 12, 929-33.
|
14 |
Wadhwa P, Goswami AK, Joshi K, Sharma SK (2005).Cyclooxygenase -2 expression increases with the stage and grade in transitional cell carcinoma of the urinary bladder. Int Urol Nephrol, 37, 47-53.
DOI
ScienceOn
|
15 |
Wulfing C, Eltze E, Von Struensee D, et al (2004). Cyclooxygenase-2 expression in bladder cancer : correlation with poor outcome after chemotherapy. Eur Urol, 45, 46-52.
DOI
ScienceOn
|
16 |
Yamada Y, Nakamura K, Inoue Y, et al (2008). Cyclooxygenase-2 expression in invasive transitional cell carcinoma of the urinary bladder. Mol Med Report, 1, 791-5.
|
17 |
Yulizar DR, Hardjowijoto S, Djatisoesanto W, Soemarno T (2008). Difference in cyclooxygenase-2 (COX-2) expression between low and high grade papillary carcinoma in human bladder cancer. Folia Medica Indonesiana, 44 ,71-5.
|
18 |
Zhu Z, Shen Z, Xu C (2012). Inflammatory pathways as promising targets to increase chemotherapy response in bladder cancer. Mediators Inflamm, 528690, 11.
|
19 |
Bulbul MA, Husseini N, Houjaji A (2005). Superficial bladder cancer epidemiology, diagnosis and management. J Med Liban, 53, 107-13.
|
20 |
Dhawan D, Craig BA, Cheng L, et al (2010). Effects of short-term celecoxib treatment in patients with invasive transitional cell carcinoma of the urinary bladder. Mol Cancer Ther, 9, 1371-7.
DOI
ScienceOn
|
21 |
Edge SB, Byrd DR, Compton CC, et al (2010). AJCC cancer staging manual, 7nd ed., Springer, New York, 497-50.
|
22 |
Epstein JI, Amin MB, Reuter VR, Mostofi FK (1998). The world Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol, 22, 1435-48.
DOI
ScienceOn
|
23 |
Jang TJ, Lee KS (2009).The expression of cyclooxygenase-2 and survivin in urinary bladder transitional cell carcinoma. Korean J Pathol, 43, 206-11.
DOI
|
24 |
Eschwege P, Ferlicot S, Droupy S, et al (2003). A histopathologic investigation of PGE (2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder. Eur Urol, 44, 435-41.
DOI
ScienceOn
|
25 |
Gangwar R, Mandhani A, Mittal RD (2011). Functional polymorphisms of cyclooxygenase-2 (COX-2) gene and risk for urinary bladder cancer in North India. Surgery, 149, 126-34.
DOI
ScienceOn
|
26 |
Gurocak S, Sozen S, Erdem O, et al (2006). Relation between cyclooxygenase-2 expression and clinicopathologic parameters with patient prognosis in transitional cell carcinoma of the bladder. Urol Int, 76, 51-6.
DOI
ScienceOn
|
27 |
Kim SI, Kwon SM, Kim YS, Hong SJ (2002). Association of cyclooxygenase-2 expression with prognosis of stage T1 grade 3 bladder cancer. Urology, 60, 816-21.
DOI
ScienceOn
|
28 |
Koki AT, Masferrer JL (2002). Celecoxib: a specific cox-2 inhibitor with anticancer properties. Cancer Control, 9, 28-35.
|
29 |
Komhoff M, Guan Y, Shappell HW, et al (2000). Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol, 157, 29-35.
DOI
ScienceOn
|
30 |
Margulis V, Shariat SF, Ashfaq R, et al (2007). Expression of cyclooxygenase-2 in normal urothelium, and superficial and advanced transitional cell carcinoma of the bladder. J Urol, 177, 1163-8.
DOI
ScienceOn
|
31 |
Matsuzawa I, Kondo Y, Kimura G, et al (2002). Cyclooxygenase-2 expression and relationship to malignant potential in human bladder cancer. J Health Sci, 48, 42-7.
DOI
ScienceOn
|
32 |
Meric JB, Rottey S, Olaussen K, et al (2006). Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol, 59, 51-64.
DOI
ScienceOn
|